Fludarabine (Flu) and IV busulfan (Bu)±ATG:: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDS -: Preliminary results.

被引：0
|
作者：
deLima, M
Shahjahan, M
Madden, T
Tran, HT
Gajewski, JL
Couriel, DR
Giralt, S
Donato, ML
Anderlini, P
Korbling, M
Khouri, I
Russell, JA
Champlin, RE
Andersson, BS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tom Baker Canc Clin, Dept Med, Calgary, AB, Canada
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5147
引用
收藏
页码：345B / 345B
页数：1
相关论文
共 50 条
  • [1] Early data using fludarabine and IV busulfan ATG as myeloablative, yet reduced toxicity conditioning regimen for allogeneic transplantation in AML and MDS
    Andersson, B
    Madden, T
    Shahjahan, M
    deLima, M
    Couriel, D
    Gajewski, J
    Giralt, S
    Donato, M
    Russell, J
    Champlin, J
    BONE MARROW TRANSPLANTATION, 2002, 29 : S74 - S75
  • [2] Pretransplant conditioning with IV busulfan (Bu) and fludarabine (Flu) as alternative to Bu and cyclophosphamide (Cy) - A safe, myeloablative regimen with high antileukemic efficacy in AML/MDS
    de Lima, M
    Couriel, D
    Shahjahan, M
    Alamo, J
    Madden, T
    Thapar, N
    Russel, J
    Anderlini, P
    Giralt, S
    Shpall, E
    Jones, R
    Champlin, R
    Andersson, B
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 63 - 63
  • [3] Allogeneic transplantation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a low-toxicity combination of intravenous (IV) Busulfan (Bu) and Fludarabine (Flu) ±ATG.
    De Lima, M
    Couriel, D
    Shahjahan, M
    Madden, T
    Gajewski, J
    Giralt, S
    Russell, J
    Champlin, RE
    Andersson, BS
    BLOOD, 2002, 100 (11) : 853A - 853A
  • [4] ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) FOR RELAPSED, REFRACTORY MYELOID LEUKEMIA AND MDS USING CLOFARABINE (CLO) ± FLUDARABINE (FLU) WITH IV BUSULFAN (BU) AS CONDITIONING THERAPY
    Andersson, B. S.
    de Lima, M.
    Popat, U.
    Jones, R. B.
    Shpall, E. J.
    Hosing, C.
    McAdams, P. L.
    Alousi, A. M.
    Kebriaei, P.
    Champlin, R. E.
    Worth, L. L.
    Madden, T. L.
    Kazerooni, R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 86 - 87
  • [5] Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    de Lima, M
    Couriel, D
    Thall, PF
    Wang, XM
    Madden, T
    Jones, R
    Shpall, EJ
    Shahjahan, M
    Pierre, B
    Giralt, S
    Korbling, M
    Russell, JA
    Champlin, RE
    Andersson, BS
    BLOOD, 2004, 104 (03) : 857 - 864
  • [6] Fludarabine/melphalan conditioning for allogeneic stem cell transplantation (SCT) in elderly patients with AML/MDS
    Kennedy, GA
    Butler, J
    Durrant, S
    Hill, GR
    Western, R
    Morton, J
    BLOOD, 2005, 106 (11) : 438B - 439B
  • [7] COMPARISON OF IV BUSULFAN AND FLUDARABINE VS IV BUSULFAN AND CYCLOPHOSPHAMIDE AS CONDITIONING REGIMEN IN MYELOABALTIVE ALLOGENEIC STEM CELL TRANSPLANTATION
    de Villambrosia, S. Gonzalez
    Moreto, A.
    Nunez, J.
    Bermudez, A.
    Yanez, L.
    Insunza, A.
    Iriondo, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 142 - 142
  • [8] Is Busulfan and Fludarabine an Optimal Myeloablative Hematopoietic Stem Cell Transplant (HSCT) Conditioning Regimen in Children with AML/MDS ?
    Ramzan, Mohammed
    Ali, Muhammad
    Krueger, Joerg
    Alexander, Sarah
    Dupuis, Lee
    Finkelstein, Yaron
    Klein, Talia
    Sung, Lillian
    Frangoul, Haydar A.
    Schechter, Tal
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S350 - S350
  • [9] Clofarabine ± fludarabine with IV busulfan as reduced-toxicity conditioning therapy for allogeneic stem cell transplantation (Allo-SCT) in advanced myeloid leukaemia/MDS
    Andersson, B.
    de Lima, M.
    Worth, L.
    Thall, P.
    Popat, U.
    Jones, R.
    Shpall, E.
    Hosing, C.
    Madden, T.
    Kazerooni, R.
    McAdams, P.
    Alousi, A.
    Kebriaei, P.
    Champlin, R.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S88 - S88
  • [10] Once daily Busulfan (Bu) and fludarabine (Flu) with allogeneic stem cell transplantation (AlloSCT) in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS): Clinical results and pharmacokinetics.
    de Lima, M
    Madden, T
    Couriel, D
    Thall, RF
    Shahjahan, M
    Giralt, S
    Anderlini, P
    Russell, J
    Shpall, EJ
    Champlin, RE
    Andersson, BS
    BLOOD, 2003, 102 (11) : 704A - 705A
12345